Liu Bojing, Fang Fang, Pedersen Nancy L, Tillander Annika, Ludvigsson Jonas F, Ekbom Anders, Svenningsson Per, Chen Honglei, Wirdefeldt Karin
From the Departments of Medical Epidemiology and Biostatistics (B.L., F.F., N.L.P., A.T., J.F.L., K.W.), Medicine (A.E.), and Clinical Neuroscience (P.S., K.W.), Karolinska Institutet, Stockholm, Sweden; Department of Psychology (N.L.P.), University of Southern California, Los Angeles; Department of Paediatrics (J.F.L.), Örebro University Hospital, Sweden; and Department of Epidemiology and Biostatistics (H.C.), College of Human Medicine, Michigan State University, East Lansing.
Neurology. 2017 May 23;88(21):1996-2002. doi: 10.1212/WNL.0000000000003961. Epub 2017 Apr 26.
To examine whether vagotomy decreases the risk of Parkinson disease (PD).
Using data from nationwide Swedish registers, we conducted a matched-cohort study of 9,430 vagotomized patients (3,445 truncal and 5,978 selective) identified between 1970 and 2010 and 377,200 reference individuals from the general population individually matched to vagotomized patients by sex and year of birth with a 40:1 ratio. Participants were followed up from the date of vagotomy until PD diagnosis, death, emigration out of Sweden, or December 31, 2010, whichever occurred first. Vagotomy and PD were identified from the Swedish Patient Register. We estimated hazard ratios (HRs) with 95% confidence intervals (CIs) using Cox models stratified by matching variables, adjusting for country of birth, chronic obstructive pulmonary disease, diabetes mellitus, vascular diseases, rheumatologic disease, osteoarthritis, and comorbidity index.
A total of 4,930 cases of incident PD were identified during 7.3 million person-years of follow-up. PD incidence (per 100,000 person-years) was 61.8 among vagotomized patients (80.4 for truncal and 55.1 for selective) and 67.5 among reference individuals. Overall, vagotomy was not associated with PD risk (HR 0.96, 95% CI 0.78-1.17). However, there was a suggestion of lower risk among patients with truncal vagotomy (HR 0.78, 95% CI 0.55-1.09), which may be driven by truncal vagotomy at least 5 years before PD diagnosis (HR 0.59, 95% CI 0.37-0.93). Selective vagotomy was not related to PD risk in any analyses.
Although overall vagotomy was not associated the risk of PD, we found suggestive evidence for a potential protective effect of truncal, but not selective, vagotomy against PD development.
探讨迷走神经切断术是否会降低帕金森病(PD)的发病风险。
利用瑞典全国登记处的数据,我们进行了一项匹配队列研究,研究对象为1970年至2010年间确定的9430例接受迷走神经切断术的患者(3445例为全迷走神经切断术,5978例为选择性迷走神经切断术),以及从普通人群中选取的377200名对照个体,这些对照个体按40:1的比例根据性别和出生年份与接受迷走神经切断术的患者进行个体匹配。从迷走神经切断术日期开始对参与者进行随访,直至诊断为PD、死亡、移民出瑞典或2010年12月31日,以先发生者为准。迷走神经切断术和PD的诊断信息来自瑞典患者登记处。我们使用Cox模型,根据匹配变量进行分层,并对出生国家、慢性阻塞性肺疾病、糖尿病、血管疾病、风湿性疾病、骨关节炎和合并症指数进行调整,估计风险比(HR)及其95%置信区间(CI)。
在730万人年的随访期间,共确诊4930例新发PD病例。接受迷走神经切断术患者的PD发病率(每10万人年)为61.8(全迷走神经切断术患者为80.4,选择性迷走神经切断术患者为55.1),对照个体的发病率为67.5。总体而言,迷走神经切断术与PD风险无关(HR 0.96,95%CI 0.78 - 1.17)。然而,有迹象表明全迷走神经切断术患者的风险较低(HR 0.78,95%CI
0.55 - 1.09),这可能是由在PD诊断前至少5年进行的全迷走神经切断术所致(HR 0.59,95%CI 0.37 - 0.93)。在任何分析中,选择性迷走神经切断术均与PD风险无关。
虽然总体上迷走神经切断术与PD风险无关,但我们发现有提示性证据表明全迷走神经切断术(而非选择性迷走神经切断术)对PD发展可能具有保护作用。